Technology
Explore the science behind our innovation—from the unmet problem we are tackling to the transformative solution we are developing. If you want to dive deeper, you will find answers to frequently asked questions at the bottom of this page.
... are the most abundant immune cells in the human body and the fastest to respond to infection. As the primary effectors of innate immunity, they are uniquely potent against both bacteria and fungi, engulfing pathogens, releasing antimicrobial enzymes, and deploying extracellular traps to neutralize threats within minutes.
Belonging to the granulocyte family, neutrophils are distinguished by their characteristic lobulated nucleus - the inspiration behind NeutroGen's logo.
Neutrophils
When neutrophils are missing
Lacking neutrophils can lead to drastically increased susceptibility to severe bacterial and fungal infections.
This condition is called neutropenia and it arises most commonly as a side effect of cancer chemotherapy, but also from bone marrow disorders, autoimmune conditions, and inherited diseases such as severe congenital neutropenia.
For these patients, even a routine infection can become life-threatening.
Why current treatments fall short
Some cases of neutropenia can be overcome by administration of Granulocyte-colony stimulating factor (G-CSF), which encourages the patient's own bone marrow to produce neutrophils. But G-CSF requires functional progenitor cells (stem cells) to work and in many patients, particularly those whose marrow has been depleted by chemotherapy or damaged by disease, those progenitors are simply not available. G-CSF is often still administered for lack of a better option, even when the clinical benefit is marginal.
An alternative treatment, called granulocyte transfusion, has been attempted since the 1960s and consists of but transfer of immune cells from healthy blood donors. A single treatment course can require collections from ten or more donors, and must be performed quickly since neutrophils survive only hours outside the body. Despite decades of effort, no clinical trial has demonstrated clear efficacy. The likely reason: it is not possible to collect enough viable, functional cells from donors before those cells begin to deteriorate.
This is the gap NeutroGen was built to close.
Allogeneic by design
CryoEndure neutrophils are manufactured from healthy donor stem cells, not from the patient. This removes the dependency on the patient's own compromised bone marrow and enables a standardized product that can be administered rapidly and economically
Cryopreservability
CryoEndure neutrophils can be frozen at -80°C and reconstituted on demand
Rapid to deploy
CryoEndure is designed for the realities of hospital logistics. Reconstitution is simple and fast, enabling clinicians to respond to neutropenic episodes as they arise rather than coordinating complex donor recruitment in a crisis
Scalable
CryoEndure neutrophils are manufactured using an ex vivo expansion process engineered for scale, permitting broad accessibility
NeutroGen's approach
CryoEndure Neutrophils
NeutroGen is developing CryoEndure, off-the-shelf, cryopreserved, lab-grown neutrophils, ready to be deployed on demand at the point of care.
Our approach is based on four pillars:
Where we are
NeutroGen is in preclinical development, advancing CryoEndure toward a first-in-human clinical trial. Our current focus is on optimizing the manufacturing process, generating in vivo efficacy and safety data, and building the regulatory and analytical foundation for a Clinical Trial Application. We are targeting the start of our first clinical study by 2031.